儿科中度至重度斑块状银屑病对免疫生物学药物的未满足需求及其影响。

IF 1.1 Q2 MEDICINE, GENERAL & INTERNAL
Einstein-Sao Paulo Pub Date : 2024-06-10 eCollection Date: 2024-01-01 DOI:10.31744/einstein_journal/2024GS0413
Ana Clara Maia Palhano, Ninna Medeiros Gutierrez, Nicolas Sousa Vecchio Dos Santos, Rita Narikawa, André Ballalai, Dimitri Luz Felipe da Silva
{"title":"儿科中度至重度斑块状银屑病对免疫生物学药物的未满足需求及其影响。","authors":"Ana Clara Maia Palhano, Ninna Medeiros Gutierrez, Nicolas Sousa Vecchio Dos Santos, Rita Narikawa, André Ballalai, Dimitri Luz Felipe da Silva","doi":"10.31744/einstein_journal/2024GS0413","DOIUrl":null,"url":null,"abstract":"<p><p>Palhano et al. demonstrate the feasibility of incorporating secukinumab and ustekinumab into the Clinical Protocol and Therapeutic Guidelines for moderate to severe psoriasis in pediatric patients.</p><p><strong>Objective: </strong>Therefore, this study aimed to evaluate the impact of secukinumab and ustekinumab against moderate-to-severe plaque psoriasis in a Brazilian pediatric population with access to public healthcare.</p><p><strong>Methods: </strong>A survey of immunobiological treatments registered for use against pediatric psoriasis at the National Health Surveillance Agency was conducted. These treatments were compared to the list available in the same treatment category in the public health system through the Clinical Protocol and Therapeutic Guidelines for psoriasis. A quantitative analysis of the data of patients treated with immunobiological drugs the previous year in accordance with the Clinical Protocol and Therapeutic Guidelines was performed using data available in the DATASUS portal.</p><p><strong>Results: </strong>The public budget impact scenarios analyzed were comparable to the investment already planned for acquiring the only available drug option.</p><p><strong>Conclusion: </strong>The incorporation of two therapeutic options in the Clinical Protocol and Therapeutic Guidelines list for moderate-to-severe pediatric psoriasis was feasible in a horizon of 5 years compared to the investment into the single option available to pediatric patients. These findings can facilitate the local analysis of budgetary impact and discussions on the feasibility of this therapeutic incorporation at the state level. Incorporation of secukinumab and ustekinumab was economically feasible. These drugs are options for those who do not respond to or have contraindications to etanercept.</p>","PeriodicalId":47359,"journal":{"name":"Einstein-Sao Paulo","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11155720/pdf/","citationCount":"0","resultStr":"{\"title\":\"Unmet need for and impact of adopting immunobiological drugs for moderate to severe plaque psoriasis in a pediatric population.\",\"authors\":\"Ana Clara Maia Palhano, Ninna Medeiros Gutierrez, Nicolas Sousa Vecchio Dos Santos, Rita Narikawa, André Ballalai, Dimitri Luz Felipe da Silva\",\"doi\":\"10.31744/einstein_journal/2024GS0413\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Palhano et al. demonstrate the feasibility of incorporating secukinumab and ustekinumab into the Clinical Protocol and Therapeutic Guidelines for moderate to severe psoriasis in pediatric patients.</p><p><strong>Objective: </strong>Therefore, this study aimed to evaluate the impact of secukinumab and ustekinumab against moderate-to-severe plaque psoriasis in a Brazilian pediatric population with access to public healthcare.</p><p><strong>Methods: </strong>A survey of immunobiological treatments registered for use against pediatric psoriasis at the National Health Surveillance Agency was conducted. These treatments were compared to the list available in the same treatment category in the public health system through the Clinical Protocol and Therapeutic Guidelines for psoriasis. A quantitative analysis of the data of patients treated with immunobiological drugs the previous year in accordance with the Clinical Protocol and Therapeutic Guidelines was performed using data available in the DATASUS portal.</p><p><strong>Results: </strong>The public budget impact scenarios analyzed were comparable to the investment already planned for acquiring the only available drug option.</p><p><strong>Conclusion: </strong>The incorporation of two therapeutic options in the Clinical Protocol and Therapeutic Guidelines list for moderate-to-severe pediatric psoriasis was feasible in a horizon of 5 years compared to the investment into the single option available to pediatric patients. These findings can facilitate the local analysis of budgetary impact and discussions on the feasibility of this therapeutic incorporation at the state level. Incorporation of secukinumab and ustekinumab was economically feasible. These drugs are options for those who do not respond to or have contraindications to etanercept.</p>\",\"PeriodicalId\":47359,\"journal\":{\"name\":\"Einstein-Sao Paulo\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.1000,\"publicationDate\":\"2024-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11155720/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Einstein-Sao Paulo\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.31744/einstein_journal/2024GS0413\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Einstein-Sao Paulo","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31744/einstein_journal/2024GS0413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

Palhano等人的研究证明了将secukinumab和ustekinumab纳入儿科中重度银屑病临床方案和治疗指南的可行性:因此,本研究旨在评估secukinumab和ustekinumab对巴西儿童中重度斑块状银屑病的影响:方法:对国家卫生监督局登记的用于治疗儿童银屑病的免疫生物疗法进行了调查。这些治疗方法与公共卫生系统通过银屑病临床方案和治疗指南提供的同类治疗方法进行了比较。利用 DATASUS 门户网站提供的数据,对上一年根据《临床方案和治疗指南》接受免疫生物药物治疗的患者数据进行了定量分析:分析得出的公共预算影响方案与已计划用于购买唯一可用药物方案的投资相当:结论:在《临床方案和治疗指南》的中度至重度儿科银屑病清单中纳入两种治疗方案,与投资于儿科患者可用的单一方案相比,在5年内是可行的。这些发现有助于当地分析预算影响,并在州一级讨论纳入这种疗法的可行性。纳入 secukinumab 和 ustekinumab 在经济上是可行的。这些药物是对 etanercept 无应答或有禁忌症的患者的选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Unmet need for and impact of adopting immunobiological drugs for moderate to severe plaque psoriasis in a pediatric population.

Palhano et al. demonstrate the feasibility of incorporating secukinumab and ustekinumab into the Clinical Protocol and Therapeutic Guidelines for moderate to severe psoriasis in pediatric patients.

Objective: Therefore, this study aimed to evaluate the impact of secukinumab and ustekinumab against moderate-to-severe plaque psoriasis in a Brazilian pediatric population with access to public healthcare.

Methods: A survey of immunobiological treatments registered for use against pediatric psoriasis at the National Health Surveillance Agency was conducted. These treatments were compared to the list available in the same treatment category in the public health system through the Clinical Protocol and Therapeutic Guidelines for psoriasis. A quantitative analysis of the data of patients treated with immunobiological drugs the previous year in accordance with the Clinical Protocol and Therapeutic Guidelines was performed using data available in the DATASUS portal.

Results: The public budget impact scenarios analyzed were comparable to the investment already planned for acquiring the only available drug option.

Conclusion: The incorporation of two therapeutic options in the Clinical Protocol and Therapeutic Guidelines list for moderate-to-severe pediatric psoriasis was feasible in a horizon of 5 years compared to the investment into the single option available to pediatric patients. These findings can facilitate the local analysis of budgetary impact and discussions on the feasibility of this therapeutic incorporation at the state level. Incorporation of secukinumab and ustekinumab was economically feasible. These drugs are options for those who do not respond to or have contraindications to etanercept.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Einstein-Sao Paulo
Einstein-Sao Paulo MEDICINE, GENERAL & INTERNAL-
CiteScore
2.00
自引率
0.00%
发文量
210
审稿时长
38 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信